Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling

Extended half-life factor IX (EHL-FIX) concentrates are a mainstay of prophylactic treatment in haemophilia B due to their prolonged plasma half-life and less frequent administration. Plasma FIX activity levels do not necessarily correlate with haemostatic efficacy, possibly due to its extravascular tissue distribution while still contributing to haemostasis. Importantly, tissue-specific exposure of EHL-FIX concentrates remains insufficiently characterised. We aimed to characterise and compare FIX distribution across plasma, extravascular and synovial tissue using physiologically based pharmacokinetic (PBPK) modelling. PBPK models were developed in PK-Sim ® /MoBi ® to simulate plasma concentration–time profiles following a 50 IU/kg dose of eftrenonacog alfa (rFIX-Fc), albutrepenonacog alfa (rIX-FP) and nonacog beta pegol (N9-GP). The models incorporated binding affinity (Kd) to collagen type IV (Col4), the neonatal Fc receptor (FcRn) and a vascular endothelial binding partner. A synovium module was implemented to estimate joint-specific exposure. Predicted extravascular distribution profiles differed markedly among EHL-FIX concentrates. rFIX-Fc demonstrated the greatest extravascular distribution, followed by rIX-FP, whereas N9-GP showed minimal distribution. For rFIX-Fc and rIX-FP, highest exposure was predicted in the spleen, lung and kidney. Kd FcRn was higher for rFIX-Fc than rIX-FP, while Kd Col4 was comparable. No Kd Col4 for N9-GP was identified. Synovial fluid concentration predictions indicated highest exposure for rFIX-Fc, modest exposure for rIX-FP and limited exposure for N9-GP. The constructed PBPK models provide a mechanistic framework for predicting distinct plasma and tissue-specific distribution profiles for three EHL-FIX concentrates, offering a quantitative basis for exploration of the relationship between extravascular and synovial exposure and bleeding outcomes in haemophilia B.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacokinetics
Published
2026-11-15
DOI
https://doi.org/10.1007/s40262-026-01716-3
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling

Ron A. A. Mathôt, Marjon H. Cnossen, Sjoerd F. Koopman, Peter J. Lenting et al.
Clinical Pharmacokinetics
Hemophilia Treatment and Research
article

Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling

Ron A. A. Mathôt, Marjon H. Cnossen, Sjoerd F. Koopman, Peter J. Lenting, Erik Sjögren
article en

Abstract

Extended half-life factor IX (EHL-FIX) concentrates are a mainstay of prophylactic treatment in haemophilia B due to their prolonged plasma half-life and less frequent administration. Plasma FIX activity levels do not necessarily correlate with haemostatic efficacy, possibly due to its extravascular tissue distribution while still contributing to haemostasis. Importantly, tissue-specific exposure of EHL-FIX concentrates remains insufficiently characterised. We aimed to characterise and compare FIX distribution across plasma, extravascular and synovial tissue using physiologically based pharmacokinetic (PBPK) modelling. PBPK models were developed in PK-Sim ® /MoBi ® to simulate plasma concentration–time profiles following a 50 IU/kg dose of eftrenonacog alfa (rFIX-Fc), albutrepenonacog alfa (rIX-FP) and nonacog beta pegol (N9-GP). The models incorporated binding affinity (Kd) to collagen type IV (Col4), the neonatal Fc receptor (FcRn) and a vascular endothelial binding partner. A synovium module was implemented to estimate joint-specific exposure. Predicted extravascular distribution profiles differed markedly among EHL-FIX concentrates. rFIX-Fc demonstrated the greatest extravascular distribution, followed by rIX-FP, whereas N9-GP showed minimal distribution. For rFIX-Fc and rIX-FP, highest exposure was predicted in the spleen, lung and kidney. Kd FcRn was higher for rFIX-Fc than rIX-FP, while Kd Col4 was comparable. No Kd Col4 for N9-GP was identified. Synovial fluid concentration predictions indicated highest exposure for rFIX-Fc, modest exposure for rIX-FP and limited exposure for N9-GP. The constructed PBPK models provide a mechanistic framework for predicting distinct plasma and tissue-specific distribution profiles for three EHL-FIX concentrates, offering a quantitative basis for exploration of the relationship between extravascular and synovial exposure and bleeding outcomes in haemophilia B.

Clinical Pharmacokinetics
Uppsala University (SE), Inserm (FR), Université Paris-Saclay (FR), Erasmus MC (NL), Erasmus MC - Sophia Children’s Hospital (NL), Hemostase Inflammation Thrombosis (FR), Amsterdam University Medical Centers (NL), University of Amsterdam (NL)
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon